Applications –

 

Radiation Countermeasure

Acute Radiation Syndrome (ARS) is an area of high unmet need, as there are no current FDA approved therapies. The unique mechanism of action of TPO-7630 increases the cells’ ability to deal with radiation-induced oxidative cell damage, promoting its survival. TPO-7630 is being developed as a therapeutic to be given before (prophylactic) or after (mitigator) radiation exposure to treat civilians, military personnel, and first responders.

Additional RLIP76 protein protects the cell from radiation exposure.

Chemical Countermeasure

Terapio is also commercializing TPO-7630 as a chemical countermeasure to treat exposure to mustard compounds, an area where again, no therapy is currently available. Similar to the radiation countermeasure application, additional RLIP76 protein is used to augment the cell’s capacity to deal with mustard exposure. However, in addition to the normal mechanism of action of enhancing the efflux of glutathione bound to 4HNE, RLIP76 also transports glutathione that has bound directly to mustard in the cell. TPO-7630 is being developed as a therapeutic to be given after (mitigator) chemical exposure to treat civilian, military and first responder populations.

Additional RLIP76 protein protects the cell from chemical exposure.

Oncology Supportive Care

Terapio is commercializing TPO-7640 for oncology supportive care. Most cancer treatments utilize cytotoxic radiotherapy or chemotherapeutic agents, or a combination thereof, which target rapidly diving cells including the mucosal membranes. This causes painful inflammation and ulceration and can lead to development of oral mucositis, esophagitis, proctitis or vaginitis. A similar mechanism of action of RLIP76 as shown in Terapio’s radiation countermeasure and chemical countermeasure studies directly applies to these conditions because these side effects of cancer therapy are initiated by the generation of oxidative stress. TPO-7640 is being developed as a therapeutic to be given before (prophylactic) or after (mitigator) radiation or chemotherapy to prevent or treat these often debilitating conditions.

Terapio

/Tĕ•rah•pē•ō/

means therapy in Esperanto, an international, constructed language introduced by Dr. L.L. Zamenhof in 1887.